EClinCloud Secures New Funding to Accelerate AI Innovation in Clinical Research
EClinCloud (Ningbo) Technology Co., Ltd., a leading AI technology company specializing in clinical research solutions,...
China Tightens Medical Device Quality Oversight: 2025 Inspection Plan Unveiled
China’s National Medical Products Administration (NMPA) has released its 2025 medical device inspection plan, outlining...
Policy Analysis: Shanghai’s 2025 Pharmaceutical Procurement Regulation and Market Implications
Shanghai’s Medical Centralized Bidding and Procurement Affairs Management Office has released its January 2025 list...
Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics
The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized...
China Unveils 2025 Medical Device Inspection Strategy to Tighten Quality Control
China’s National Medical Products Administration (NMPA) convened a pivotal conference in Chengdu on March 24...
Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma
Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton...
Sinovac Biotech’s SNA02-48 Gains Clinical Approval for Tetanus Prevention
Beijing Sinovac Biotech Co., Ltd’s (NASDAQ: SVA) subsidiary Sinovac Life Sciences Co., Ltd. and its...
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement
Shanghai has finalized its list of second-tier backup suppliers and manufacturers for specialized drug formulations...
Abbott Laboratories’ Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment
US-based Abbott Laboratories (NYSE: ABT) has announced the receipt of the CE mark in the...
Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy
US-based eye care firm Alcon Laboratories, Inc. has announced the acquisition of a majority stake...
Genmab’s Tivdak Approved in Japan for Advanced Cervical Cancer Treatment
Denmark-based Genmab A/S (NASDAQ: GMAB) has secured approval from the Japan Ministry of Health, Labour...
CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues...
TransThera and Akeso Biopharma Collaborate on HCC Study with Tinengotinib and Bispecific Antibodies
Chinese companies TransThera Sciences (Nanjing) Inc. and Akeso Biopharma (HKG: 9926) have formed a strategic...
NMPA Approves Qingfeng’s Suraxavir Marboxil for Influenza A and B Treatment
China’s National Medical Products Administration (NMPA) has approved suraxavir marboxil, a Category 1 drug developed...
Medtronic Launches Digital Innovation Base in Beijing’s BioPark
US-Irish firm Medtronic (NYSE: MDT) has inaugurated its digital medical innovation base at the BioPark...
Huadong Medicine Gains NMPA Approval for HDM3019 Rheumatoid Arthritis Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced receiving approval from the National Medical Products...
Lee’s Pharmaceutical Holdings Ltd Reports 32.9% Revenue Growth in 2023
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) released its 2023 financial report, recording HKD 1.4...
RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth
China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording...
JW Therapeutics Sees 9% Revenue Decline in 2024 Amid Commercial Strategy Shift
China-based JW Therapeutics (HKG: 2126) released its 2024 financial report, recording RMB 158.2 million (USD...
Ascentage Pharma’s Revenue Soars 342% in 2024 on Strong Drug Sales and Partnerships
China-based Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) unveiled its 2024 financials, showing revenues...